Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases

Faisa Omar, Jane E. Findlay, Gemma Carfray, Robert W. Allcock, Zhong Jiang, Caitlin Moore, Amy L. Muir, Morgane Lannoy, Bracy A. Fertig, Deborah Mai, Jonathan P. Day, Graeme Bolger, George S. Baillie, Erik Schwiebert, Enno Klussmann, Nigel J. Pyne, Albert C.M. Ong, Keith Bowers, Julia M. Adam, David R. Adams & 2 others Miles D. Houslay, David J. P. Henderson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) enzymes degrade cAMP and underpin the compartmentalization of cAMP signaling through their targeting to particular protein complexes and intracellular locales. We describe the discovery and characterization of a small-molecule compound that allosterically activates PDE4 long isoforms. This PDE4-specific activator displays reversible, noncompetitive kinetics of activation (increased V max with unchanged K m), phenocopies the ability of protein kinase A (PKA) to activate PDE4 long isoforms endogenously, and requires a dimeric enzyme assembly, as adopted by long, but not by short (monomeric), PDE4 isoforms. Abnormally elevated levels of cAMP provide a critical driver of the underpinning molecular pathology of autosomal dominant polycystic kidney disease (ADPKD) by promoting cyst formation that, ultimately, culminates in renal failure. Using both animal and human cell models of ADPKD, including ADPKD patient-derived primary cell cultures, we demonstrate that treatment with the prototypical PDE4 activator compound lowers intracellular cAMP levels, restrains cAMP-mediated signaling events, and profoundly inhibits cyst formation. PDE4 activator compounds thus have potential as therapeutics for treating disease driven by elevated cAMP signaling as well as providing a tool for evaluating the action of long PDE4 isoforms in regulating cAMP-mediated cellular processes.

LanguageEnglish
Pages13320-13329
Number of pages10
JournalProceedings of the National Academy of Sciences of the United States of America
Volume116
Issue number27
Early online date17 Jun 2019
DOIs
Publication statusPublished - 2 Jul 2019

Fingerprint

Type 4 Cyclic Nucleotide Phosphodiesterase
Phosphoric Diester Hydrolases
Cyclic AMP
Molecules
Autosomal Dominant Polycystic Kidney
Protein Isoforms
Cysts
Primary Cell Culture
Molecular Pathology
Pathology
Enzymes
Cyclic AMP-Dependent Protein Kinases
Cell culture
Renal Insufficiency
Animals
Chemical activation
Cells
Kinetics

Keywords

  • PDE4
  • PDE4 activator
  • cyclic AMP
  • ADPKD
  • phosphodiesterase

Cite this

Omar, F., Findlay, J. E., Carfray, G., Allcock, R. W., Jiang, Z., Moore, C., ... Henderson, D. J. P. (2019). Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. Proceedings of the National Academy of Sciences of the United States of America, 116(27), 13320-13329. https://doi.org/10.1073/pnas.1822113116
Omar, Faisa ; Findlay, Jane E. ; Carfray, Gemma ; Allcock, Robert W. ; Jiang, Zhong ; Moore, Caitlin ; Muir, Amy L. ; Lannoy, Morgane ; Fertig, Bracy A. ; Mai, Deborah ; Day, Jonathan P. ; Bolger, Graeme ; Baillie, George S. ; Schwiebert, Erik ; Klussmann, Enno ; Pyne, Nigel J. ; Ong, Albert C.M. ; Bowers, Keith ; Adam, Julia M. ; Adams, David R. ; Houslay, Miles D. ; Henderson, David J. P. / Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. In: Proceedings of the National Academy of Sciences of the United States of America. 2019 ; Vol. 116, No. 27. pp. 13320-13329.
@article{9c868076860e4cd999cf849785fbee25,
title = "Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases",
abstract = "Cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) enzymes degrade cAMP and underpin the compartmentalization of cAMP signaling through their targeting to particular protein complexes and intracellular locales. We describe the discovery and characterization of a small-molecule compound that allosterically activates PDE4 long isoforms. This PDE4-specific activator displays reversible, noncompetitive kinetics of activation (increased V max with unchanged K m), phenocopies the ability of protein kinase A (PKA) to activate PDE4 long isoforms endogenously, and requires a dimeric enzyme assembly, as adopted by long, but not by short (monomeric), PDE4 isoforms. Abnormally elevated levels of cAMP provide a critical driver of the underpinning molecular pathology of autosomal dominant polycystic kidney disease (ADPKD) by promoting cyst formation that, ultimately, culminates in renal failure. Using both animal and human cell models of ADPKD, including ADPKD patient-derived primary cell cultures, we demonstrate that treatment with the prototypical PDE4 activator compound lowers intracellular cAMP levels, restrains cAMP-mediated signaling events, and profoundly inhibits cyst formation. PDE4 activator compounds thus have potential as therapeutics for treating disease driven by elevated cAMP signaling as well as providing a tool for evaluating the action of long PDE4 isoforms in regulating cAMP-mediated cellular processes.",
keywords = "PDE4, PDE4 activator, cyclic AMP, ADPKD, phosphodiesterase",
author = "Faisa Omar and Findlay, {Jane E.} and Gemma Carfray and Allcock, {Robert W.} and Zhong Jiang and Caitlin Moore and Muir, {Amy L.} and Morgane Lannoy and Fertig, {Bracy A.} and Deborah Mai and Day, {Jonathan P.} and Graeme Bolger and Baillie, {George S.} and Erik Schwiebert and Enno Klussmann and Pyne, {Nigel J.} and Ong, {Albert C.M.} and Keith Bowers and Adam, {Julia M.} and Adams, {David R.} and Houslay, {Miles D.} and Henderson, {David J. P.}",
year = "2019",
month = "7",
day = "2",
doi = "10.1073/pnas.1822113116",
language = "English",
volume = "116",
pages = "13320--13329",
journal = "Proceedings of the National Academy of Sciences",
issn = "1091-6490",
number = "27",

}

Omar, F, Findlay, JE, Carfray, G, Allcock, RW, Jiang, Z, Moore, C, Muir, AL, Lannoy, M, Fertig, BA, Mai, D, Day, JP, Bolger, G, Baillie, GS, Schwiebert, E, Klussmann, E, Pyne, NJ, Ong, ACM, Bowers, K, Adam, JM, Adams, DR, Houslay, MD & Henderson, DJP 2019, 'Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases' Proceedings of the National Academy of Sciences of the United States of America, vol. 116, no. 27, pp. 13320-13329. https://doi.org/10.1073/pnas.1822113116

Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. / Omar, Faisa; Findlay, Jane E.; Carfray, Gemma; Allcock, Robert W.; Jiang, Zhong; Moore, Caitlin; Muir, Amy L.; Lannoy, Morgane ; Fertig, Bracy A. ; Mai, Deborah ; Day, Jonathan P. ; Bolger, Graeme; Baillie, George S.; Schwiebert, Erik ; Klussmann, Enno ; Pyne, Nigel J.; Ong, Albert C.M.; Bowers, Keith; Adam, Julia M.; Adams, David R.; Houslay, Miles D.; Henderson, David J. P.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, No. 27, 02.07.2019, p. 13320-13329.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases

AU - Omar, Faisa

AU - Findlay, Jane E.

AU - Carfray, Gemma

AU - Allcock, Robert W.

AU - Jiang, Zhong

AU - Moore, Caitlin

AU - Muir, Amy L.

AU - Lannoy, Morgane

AU - Fertig, Bracy A.

AU - Mai, Deborah

AU - Day, Jonathan P.

AU - Bolger, Graeme

AU - Baillie, George S.

AU - Schwiebert, Erik

AU - Klussmann, Enno

AU - Pyne, Nigel J.

AU - Ong, Albert C.M.

AU - Bowers, Keith

AU - Adam, Julia M.

AU - Adams, David R.

AU - Houslay, Miles D.

AU - Henderson, David J. P.

PY - 2019/7/2

Y1 - 2019/7/2

N2 - Cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) enzymes degrade cAMP and underpin the compartmentalization of cAMP signaling through their targeting to particular protein complexes and intracellular locales. We describe the discovery and characterization of a small-molecule compound that allosterically activates PDE4 long isoforms. This PDE4-specific activator displays reversible, noncompetitive kinetics of activation (increased V max with unchanged K m), phenocopies the ability of protein kinase A (PKA) to activate PDE4 long isoforms endogenously, and requires a dimeric enzyme assembly, as adopted by long, but not by short (monomeric), PDE4 isoforms. Abnormally elevated levels of cAMP provide a critical driver of the underpinning molecular pathology of autosomal dominant polycystic kidney disease (ADPKD) by promoting cyst formation that, ultimately, culminates in renal failure. Using both animal and human cell models of ADPKD, including ADPKD patient-derived primary cell cultures, we demonstrate that treatment with the prototypical PDE4 activator compound lowers intracellular cAMP levels, restrains cAMP-mediated signaling events, and profoundly inhibits cyst formation. PDE4 activator compounds thus have potential as therapeutics for treating disease driven by elevated cAMP signaling as well as providing a tool for evaluating the action of long PDE4 isoforms in regulating cAMP-mediated cellular processes.

AB - Cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) enzymes degrade cAMP and underpin the compartmentalization of cAMP signaling through their targeting to particular protein complexes and intracellular locales. We describe the discovery and characterization of a small-molecule compound that allosterically activates PDE4 long isoforms. This PDE4-specific activator displays reversible, noncompetitive kinetics of activation (increased V max with unchanged K m), phenocopies the ability of protein kinase A (PKA) to activate PDE4 long isoforms endogenously, and requires a dimeric enzyme assembly, as adopted by long, but not by short (monomeric), PDE4 isoforms. Abnormally elevated levels of cAMP provide a critical driver of the underpinning molecular pathology of autosomal dominant polycystic kidney disease (ADPKD) by promoting cyst formation that, ultimately, culminates in renal failure. Using both animal and human cell models of ADPKD, including ADPKD patient-derived primary cell cultures, we demonstrate that treatment with the prototypical PDE4 activator compound lowers intracellular cAMP levels, restrains cAMP-mediated signaling events, and profoundly inhibits cyst formation. PDE4 activator compounds thus have potential as therapeutics for treating disease driven by elevated cAMP signaling as well as providing a tool for evaluating the action of long PDE4 isoforms in regulating cAMP-mediated cellular processes.

KW - PDE4

KW - PDE4 activator

KW - cyclic AMP

KW - ADPKD

KW - phosphodiesterase

U2 - 10.1073/pnas.1822113116

DO - 10.1073/pnas.1822113116

M3 - Article

VL - 116

SP - 13320

EP - 13329

JO - Proceedings of the National Academy of Sciences

T2 - Proceedings of the National Academy of Sciences

JF - Proceedings of the National Academy of Sciences

SN - 1091-6490

IS - 27

ER -